Mexicor®

Мексикор®

About the product

Trade name: Mexicor®

Dosage form: capsules

Ingredients: each capsule contains the active ingredient: ethylmethylhydroxypyridine succinate – 100 mg; excipients: potato starch – 54.5 mg, lactose (milk sugar) – 40 mg, povidone K17 (low-molecular-weight medical polyvinylpyrrolidone) – 4 mg, microcrystalline cellulose – 1 mg, magnesium stearate – 0.5 mg; hard gelatin capsules No. 2 composition: gelatin – up to 100%, purified water – 14–15%, titanium dioxide (E171) – 1.22 mg, Sunset Yellow dye (E110) – 0.0036 mg, Quinoline Yellow dye (E104) – 0.4575 mg

For the patient

Medicinal product for improving metabolism and cerebral blood flow, microcirculation, and blood rheology, as well as reducing platelet aggregation

Indications for use:

  • Coronary heart disease (as part of combination therapy)
  • Consequences of acute cerebrovascular accidents, including post–transient ischemic attacks, during the subcompensation phase, as part of preventive treatment courses
  • Mild traumatic brain injury, post-traumatic brain injury conditions
  • Encephalopathies of various origins (dyscirculatory, dysmetabolic, post-traumatic, mixed)
  • Functional disorders of the autonomic nervous system (vegetative dystonia syndrome)
  • Mild cognitive disorders of atherosclerotic origin
  • Anxiety disorders in neurotic and neurosis-like conditions
  • Management of withdrawal syndrome in alcoholism with predominant neurotic and autonomic-vascular symptoms; post-withdrawal disorders
  • Conditions following acute intoxication with antipsychotic agents
  • Asthenic conditions and for the prevention of somatic diseases caused by extreme factors and stress
  • Exposure to extreme (stressful) factors

Contraindications:

  • Hypersensitivity to the active substance or any other component of the product
  • Acute liver failure
  • Acute renal failure
  • Children under 18 years of age (safety and efficacy in pediatric patients have not been established)
  • Pregnancy
  • Breastfeeding
  • Rare hereditary intolerance to galactose, lactase deficiency, glucose-galactose malabsorption syndrome (the product contains lactose)

 

Contact us

Select a service*

Pharmacovigilance

MiraxBioPharma is committed to ensuring the quality and safety of its products and pays special attention to collecting and analyzing information about adverse reactions and complaints associated with the use of our products.

If you become aware of any adverse reactions to the medicinal product Cezarox® Epi or of a lack of therapeutic effect, please report it via email at: adversareaction@drugsafety.ru or by phone: +7 (800) 777-86-04.

If you become aware of any adverse reactions to other MiraxBioPharma medicinal products or of a lack of therapeutic effect, please report it via email at: GVP@mbpharma.ru, by phone: +7 (495) 183-38-41 or by filling out the electronic form below

Adverse reaction reporting form
Specify gender*
Suspected medicinal product information
Reporter information

Preferred method of contact*
We use cookies

By using this website, you consent to the collection and processing of your personal data, including through third-party services, and the use of cookies and web analytics tools, under the terms outlined in the Personal Data Processing Policy.